RBC Capital Maintains Outperform on 89bio, Lowers Price Target to $27
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has maintained an 'Outperform' rating on 89bio (NASDAQ:ETNB) but lowered the price target from $34 to $27.
October 11, 2023 | 12:36 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
89bio's price target has been lowered from $34 to $27 by RBC Capital, though the 'Outperform' rating is maintained.
The lowering of the price target by RBC Capital could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintained 'Outperform' rating indicates that the analyst still sees potential in the stock, which could counterbalance the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100